5,35 €
2,57 % heute
L&S, 7. Oktober, 16:29 Uhr
ISIN
US30052C1071
Symbol
EOLS
Berichte

Evolus, Inc. Aktie News

Neutral
PRNewsWire
15 Tage alt
Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partnership underscores Evolus' commitment to patient safety and provider education for their new FDA-approved filler line.
Neutral
Business Wire
25 Tage alt
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,744 shares of Evolus common stock and an aggregate of 15,000 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-exe...
Neutral
Business Wire
29 Tage alt
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025. Ms. Mitchell has over 20 years of strategic and operational finance leadership across both public and private companie...
Neutral
Business Wire
etwa ein Monat alt
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. “Achieving positive topline results in our mid-face study i...
Neutral
Business Wire
etwa 2 Monate alt
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to rest...
Neutral
Business Wire
etwa 2 Monate alt
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in August of an aggregate of 12,731 restricted stock units (RSUs) of the company's common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committe...
Neutral
The Motley Fool
2 Monate alt
Evolus (EOLS) Q2 Revenue Rises 4%
Neutral
Seeking Alpha
2 Monate alt
Evolus, Inc. (NASDAQ:EOLS ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants David Moatazedi - President, CEO & Director Nareg Sagherian - Head of Global Investor Relations & Corporate Communications Rui Avelar - Chief Medical Officer and Head of Research & Development Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Rese...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen